1. Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991; 40:55–65.
2. Carey MS, O'Connell GJ, Johanson CR, Goodyear MD, Murphy KJ, Daya DM, et al. Good outcome associated with a standardized treatment protocol using selective postoperative radiation in patients with clinical stage I adenocarcinoma of the endometrium. Gynecol Oncol. 1995; 57:138–144.
3. Mariani A, Webb MJ, Keeney GL, Haddock MG, Calori G, Podratz KC. Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol. 2000; 182:1506–1519.
4. Schink JC, Rademaker AW, Miller DS, Lurain JR. Tumor size in endometrial cancer. Cancer. 1991; 67:2791–2794.
5. Elliott P, Green D, Coates A, Krieger M, Russell P, Coppleson M, et al. The efficacy of postoperative vaginal irradiation in preventing vaginal recurrence in endometrial cancer. Int J Gynecol Cancer. 1994; 4:84–93.
6. Leijon T, Rosenberg P, Boeryd B. Total abdominal hysterectomy and bilateral salpingo-oophorectomy. A sufficient treatment for patients with low risk endometrial carcinoma. Int J Gynecol Cancer. 1997; 7:376–380.
7. Poulsen HK, Jacobsen M, Bertelsen K, Andersen JE, Ahrons S, Bock J, et al. Adjuvant radiation therapy is not necessary in the management of endometrial carcinoma stage I, low-risk cases. Int J Gynecol Cancer. 1996; 6:38–43.
8. Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. J Natl Cancer Inst. 2012; 104:1625–1634.
9. Scholten AN, van Putten WL, Beerman H, Smit VT, Koper PC, Lybeert ML, et al. Postoperative radiotherapy for stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys. 2005; 63:834–838.
10. Nugent EK, Bishop EA, Mathews CA, Moxley KM, Tenney M, Mannel RS, et al. Do uterine risk factors or lymph node metastasis more significantly affect recurrence in patients with endometrioid adenocarcinoma? Gynecol Oncol. 2012; 125:94–98.
11. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004; 92:744–751.
12. Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24:Suppl 6. vi33–vi38.
13. Jeppesen MM, Jensen PT, Gilså Hansen D, Iachina M, Mogensen O. The nature of early-stage endometrial cancer recurrence-a national cohort study. Eur J Cancer. 2016; 69:51–60.
14. Jeppesen MM, Mogensen O, Hansen DG, Iachina M, Korsholm M, Jensen PT. Detection of recurrence in early stage endometrial cancer - the role of symptoms and routine follow-up. Acta Oncol. 2017; 56:262–269.
15. Mahdi H, Munkarah AR, Ali-Fehmi R, Woessner J, Shah SN, Moslemi-Kebria M. Tumor size is an independent predictor of lymph node metastasis and survival in early stage endometrioid endometrial cancer. Arch Gynecol Obstet. 2015; 292:183–190.
16. Vargas R, Rauh-Hain JA, Clemmer J, Clark RM, Goodman A, Growdon WB, et al. Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis. Gynecol Oncol. 2014; 133:216–220.
17. Straughn JM Jr, Huh WK, Kelly FJ, Leath CA 3rd, Kleinberg MJ, Hyde J Jr, et al. Conservative management of stage I endometrial carcinoma after surgical staging. Gynecol Oncol. 2002; 84:194–200.
18. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64:9–29.
19. McAlpine JN, Temkin SM, Mackay HJ. Endometrial cancer: not your grandmother's cancer. Cancer. 2016; 122:2787–2798.
20. Robbins JR, Yechieli R, Laser B, Mahan M, Rasool N, Elshaikh MA. Is time to recurrence after hysterectomy predictive of survival in patients with early stage endometrial carcinoma? Gynecol Oncol. 2012; 127:38–42.
21. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009; 105:103–104.
22. Mariani A, Dowdy SC, Keeney GL, Haddock MG, Lesnick TG, Podratz KC. Predictors of vaginal relapse in stage I endometrial cancer. Gynecol Oncol. 2005; 97:820–827.
23. Mariani A, Webb MJ, Keeney GL, Aletti G, Podratz KC. Predictors of lymphatic failure in endometrial cancer. Gynecol Oncol. 2002; 84:437–442.
24. Mariani A, Webb MJ, Keeney GL, Aletti G, Podratz KC. Endometrial cancer: predictors of peritoneal failure. Gynecol Oncol. 2003; 89:236–242.
25. Mariani A, Webb MJ, Keeney GL, Calori G, Podratz KC. Hematogenous dissemination in corpus cancer. Gynecol Oncol. 2001; 80:233–238.
26. Abeler VM, Kjørstad KE. Endometrial adenocarcinoma in Norway. A study of a total population. Cancer. 1991; 67:3093–3103.
27. Fung-Kee-Fung M, Dodge J, Elit L, Lukka H, Chambers A, Oliver T; Cancer Care Ontario Program in Evidence-based Care Gynecology Cancer Disease Site Group. Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecol Oncol. 2006; 101:520–529.
28. Orr JW Jr, Holimon JL, Orr PF. Stage I corpus cancer: is teletherapy necessary? Am J Obstet Gynecol. 1997; 176:777–788.
29. Alektiar KM, McKee A, Venkatraman E, McKee B, Zelefsky MJ, Mychalczak BR, et al. Intravaginal high-dose-rate brachytherapy for Stage IB (FIGO Grade 1, 2) endometrial cancer. Int J Radiat Oncol Biol Phys. 2002; 53:707–713.
30. O'Brien DJ, Flannelly G, Mooney EE, Foley M. Lymphovascular space involvement in early stage well-differentiated endometrial cancer is associated with increased mortality. BJOG. 2009; 116:991–994.
31. dos Reis R, Burzawa JK, Tsunoda AT, Hosaka M, Frumovitz M, Westin SN, et al. Lymphovascular space invasion portends poor prognosis in low-risk endometrial cancer. Int J Gynecol Cancer. 2015; 25:1292–1299.
32. Lee JY, Kim JH, Seo JW, Kim HS, Kim JW, Park NH, et al. Detecting asymptomatic recurrence in early-stage endometrial cancer: the value of vaginal cytology, imaging studies, and CA-125. Int J Gynecol Cancer. 2016; 26:1434–1439.
33. Therasakvichya S, Kuljarusnont S, Petsuksiri J, Chaopotong P, Achariyapota V, Srichaikul P, et al. Clinical outcomes of stage I endometrial carcinoma patients treated with surgery alone: Siriraj Hospital experiences. J Gynecol Oncol. 2016; 27:e48.
34. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000; 355:1404–1411.
35. Menczer J. Endometrial carcinoma. Is routine intensive periodic follow-up of value? Eur J Gynaecol Oncol. 2000; 21:461–465.
36. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol. 2003; 89:201–209.
37. Xu Y, Burmeister C, Hanna RK, Munkarah A, Elshaikh MA. Predictors of survival after recurrence in women with early-stage endometrial carcinoma. Int J Gynecol Cancer. 2016; 26:1137–1142.